(1244-A) Ceramide scoring for Cardiovascular Disease risk prediction using Agilent Rapidfire SPE-MS/MS
Monday, February 5, 2024
12:00 PM – 1:00 PM EST
Location: Exhibit Halls AB
Abstract: Cardiovascular diseases (CVDs) have been steadily rising in recent years, culminating in their contribution to 32.0% of worldwide fatalities in 2021. Ceramides, a class of sphingolipids, have been used as biomarkers for CVD and diabetes. Specifically, four ceramide species (Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/24:0, and Cer d18:1/24:1) are utilized for predicting Major Adverse Cardiovascular Events (MACE). We present an efficient screening method for these four ceramides in human plasma, employing the Agilent Rapidfire capabilities for online SPE-MS/MS high-throughput analysis (~15 secs/sample). The use of authentic deuterium labelled standards enables absolute quantitation of each ceramide within physiologic dynamic ranges. A validation of our methodology using biological samples was supported by highly correlated values when compared to established LC-MS/MS methods employed in research labs and clinics. Our results illustrate the potential of the Rapidfire for high-throughput screening in both research and clinical applications, addressing scalability issues present in existing technologies while ensuring robust and reproducible outcomes.